Patients and interventions: 327 ambulatory patients diagnosed with radio-graphically confirmed community-acquired pneumonia administered clarithromycin 500mg immediate-release or amoxicillin ...

The clinical cure rate was significantly lower in the amoxicillin-clavulanate group than in the ciprofloxacin group (58% vs. 77%), regardless of whether the pathogens were susceptible or resistant ...

Sandoz (SDZNY) announced that the European Commission, or EC, has granted marketing authorization for Afqlir 2 mg vial kit and pre-filled syringe for intravitreal injection, a biosimilar to ...

The best antibiotic to treat pneumonia will depend on several factors, such as your type of pneumonia, age, lifestyle, and medical history. Zithromax (azithromycin) is often the first-line treatment ...

Tooth decay occurs when bacteria in the mouth produce acids that attack the enamel, or protective outer layer of the tooth. If left untreated, tooth decay could lead to gum disease, cavities, and ...

Swiss generic medicines firm Sandoz on Tuesday said it had reached a $275 million settlement with plaintiffs in a legacy US generic drug antitrust lawsuit. Sandoz and subsidiary Fougera ...

Novartis' soon-to-be-divested Sandoz unit has positive clinical trial data in hand for a biosimilar of Amgen's blockbuster osteoporosis therapy Prolia (denosumab), clearing the way for regulatory ...

Clove oil is a natural alternative for treating mild mouth or tooth pain, but the scientific evidence for it is insufficient to replace seeing an oral healthcare provider for a toothache.

Antibiotic treatment is not recommended for acute bronchitis in immunocompetent patients in industrialised countries. Whether these recommendations are relevant to the developing world and to ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Newly independent drugmaker Sandoz has made its first acquisition since spinning out of Novartis last October, buying a brand from Coherus that will boost its position in biosimilar medicines and ...

Les Masterson is a deputy editor and insurance analyst at Forbes Advisor. He has been a journalist, reporter, editor and content creator for more than 25 years. He has covered insurance for a ...